GlobalData on MSN2d
Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody ...
The Lancet2d
Guselkumab in the IL-23 inhibition landscape for ulcerative colitis
The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum ...
BioPharma Dive3d
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and Roche, each of which were acquired in multibillion-dollar deals.
FierceBiotech3d
Sanofi, Teva look to 'next frontier' in IBD treatment after TL1A antibody hits mark in midstage trial
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...